Pharmacist Information Hub

How to dispense S4 therapeutic vapes

Understanding the prescribing pathways

All scripts for therapeutic vapes must be prescribed under one of the TGA’s three special access pathways for unlicensed medicines:

Authorised Prescriber (AP) Scheme

Special Access Scheme B (SAS-B)

Special Access Scheme C (SAS-C)

Validating a prescription for S4 vapes

When pharmacists receive a script for therapeutic vapes, they must establish under which special access pathway the clinician has prescribed.

In particular, the pharmacist should check the script for an SAS Authority number (starting with either MAP, MB or MC) plus any supporting documentation.

Authorised Prescriber (AP) Scheme

e.g. MAPYY/01234567

Special Access Scheme B (SAS-B)

e.g. MBYY/01234567

Special Access Scheme C (SAS-C)

e.g. MCYY/01234567

Using the SAS Portal to validate a prescription

The TGA has created a new validation tool within its existing SAS Portal. Pharmacists can now use this tool to check information associated with a script.

  1. Log in to the SAS Portal and select ‘SAS/AP Submission Validation’ from the top menu bar
  2. Enter the Authorisation or Notification reference number on the patient’s script and select ‘Search
  3. The validation tool will display the details associated with the reference number allowing you to validate that the prescription has been appropriately authorised
  4. Once verified, you can proceed to dispense immediately

Submitting an SAS-C notification when a script cannot be validated

If the script does not contain an authorisation number, the TGA’s validation tool will not be able to confirm the validity of the prescription.

If patient is neither pregnant nor below 16, pharmacists may assume that the script is issued under SAS-C.

The TGA’s guidelines allow pharmacists to lodge an SAS-C notification on behalf of the prescriber through the TGA’s SAS Portal, allowing you to dispense immediately. It is best practice to inform prescribers when you have filed an SAS-C notification on behalf of their patient.

Supplying and Dispensing Therapeutic Vapes
Nicovape Q products are TGA notified therapeutic vaping goods indicated for smoking cessation or the management of nicotine dependence. TGA Notification ID numbers: VG-2024-NTF-00234, VG-2024-NTF-00241, VG-2024-NTF-00240, VG-2024-NTF-00235, VG-2024-NTF-00242, VG-2024-NTF-00239, VG-2024-NTF-00237, VG-2024-NTF-00243, VG-2024-NTF-00238, VG-2024-NTF-00236.

© 2024 Liber Pharmaceuticals Ltd. All content

iNRT Healthcare is operated by Liber Pharmaceuticals for the purpose of furthering healthcare education regarding Nicotine Vaping Products (NVPs) within the Australian medical framework. Liber has no affiliation with the tobacco industry, their affiliates, or any organisations or individuals engaged in lobbying on their behalf.

This site is intended for use only by Australian-registered healthcare professionals with an interest in smoking cessation. It is not intended for use by consumers.